Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-945-7361
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.42 million
Profitability
Miscellaneous
Employees81
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable
Translate Bio (NASDAQ:TBIO) Frequently Asked Questions
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
How were Translate Bio's earnings last quarter?
Translate Bio Inc (NASDAQ:TBIO) issued its quarterly earnings data on Wednesday, July, 31st. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.09. The company had revenue of $1.17 million for the quarter, compared to analyst estimates of $1.73 million. Translate Bio had a negative return on equity of 84.22% and a negative net margin of 2,696.98%. View Translate Bio's Earnings History.
When is Translate Bio's next earnings date?
What price target have analysts set for TBIO?
5 Wall Street analysts have issued 12-month price targets for Translate Bio's shares. Their forecasts range from $17.00 to $25.00. On average, they expect Translate Bio's stock price to reach $21.60 in the next year. This suggests a possible upside of 126.2% from the stock's current price. View Analyst Price Targets for Translate Bio.
What is the consensus analysts' recommendation for Translate Bio?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Translate Bio.
What are Wall Street analysts saying about Translate Bio stock?
Here are some recent quotes from research analysts about Translate Bio stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to achievement of target price. Our price target of $21/share is based on an equally-weighted composite of: (a) $16.9/share, as a 35x multiple of taxed and diluted $4.33 discounted back to FY19 at 18% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $25.6/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/1/2019)
- 2. According to Zacks Investment Research, "Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. " (7/16/2019)
Has Translate Bio been receiving favorable news coverage?
News coverage about TBIO stock has trended very negative on Monday, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Translate Bio earned a news impact score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Translate Bio.
Are investors shorting Translate Bio?
Translate Bio saw a increase in short interest in October. As of October 31st, there was short interest totalling 5,110,000 shares, an increase of 12.6% from the September 30th total of 4,540,000 shares. Based on an average daily volume of 319,000 shares, the short-interest ratio is presently 16.0 days. Approximately 13.4% of the company's shares are short sold. View Translate Bio's Current Options Chain.
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Regenxbio (RGNX), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Coherus Biosciences (CHRS), Sangamo Therapeutics (SGMO), Aerie Pharmaceuticals (AERI), Editas Medicine (EDIT), Fate Therapeutics (FATE), NanoString Technologies (NSTG), Rubius Therapeutics (RUBY), Vericel (VCEL) and AVITA MED LTD/S (RCEL).
What other stocks do shareholders of Translate Bio own?
Who are Translate Bio's key executives?
Translate Bio's management team includes the folowing people:
- Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)
- Dr. Michael W. Heartlein, Chief Technology Officer (Age 60)
- Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 54)
- Dr. Richard Wooster, Chief Scientific Officer (Age 59)
- Mr. Paul D. Burgess J.D., Chief Legal Officer & Corp. Sec. (Age 45)
When did Translate Bio IPO?
(TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.
Who are Translate Bio's major shareholders?
Translate Bio's stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.03%), First Allied Advisory Services Inc. (0.03%), McGuire Investment Group LLC (0.02%) and Gamco Investors INC. ET AL (0.02%). Company insiders that own Translate Bio stock include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Institutional Ownership Trends for Translate Bio.
Which major investors are buying Translate Bio stock?
TBIO stock was acquired by a variety of institutional investors in the last quarter, including First Allied Advisory Services Inc., McGuire Investment Group LLC, Gamco Investors INC. ET AL and California Public Employees Retirement System. Company insiders that have bought Translate Bio stock in the last two years include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Insider Buying and Selling for Translate Bio.
How do I buy shares of Translate Bio?
Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Translate Bio's stock price today?
One share of TBIO stock can currently be purchased for approximately $9.55.
How big of a company is Translate Bio?
Translate Bio has a market capitalization of $487.15 million and generates $1.42 million in revenue each year. The company earns $-97,390,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. Translate Bio employs 81 workers across the globe.View Additional Information About Translate Bio.
What is Translate Bio's official website?
How can I contact Translate Bio?
Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.
MarketBeat Community Rating for Translate Bio (NASDAQ TBIO)
MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote "Outperform" if you believe TBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
